Skip to main content
. 2024 May 16;38(7):1455–1468. doi: 10.1038/s41375-024-02267-x

Table 2.

Implementation of NGS test in the diagnostics.

Commercial IVD/IVDR/FDA assaya Laboratory-developed test (in-house/custom)
Process Tools, material Steps to be fulfilled Steps to be fulfilled Specifications and TP53-CLL-specific notes
Test familiarization Explore the clinical and analytical needs Define turnaround time, costs, number of samples, instrumentation, personnel, etc. Standalone or panel assay
Test development Study available technologies Choose a commercial method Test design

Regions to be sequenced

Library preparation method

Sequencing technology

Bioinformatics

Determine required test performance metrics and sequencing settings

Aim to detect low-VAF variants

Consider: DNA input, coverage (each base of TP53 gene has to meet the minimum read depth)

Prepare SOP
Optimization

Perform pilot run(s)

Reference material

Non-DNA controls

General assessment of method applicability for the purpose Identify and solve errors and weaknesses
Check if the required parameters are met
Set the critical values (pass/fail criteria)

Output library quality and quantity

Sequencing performance (level of background noise/overall error rate, coverage non-uniformity, low/high coverage, base call quality metrics etc.)

Verification/validation Reference material (different from the material used during optimization) Verification Prepare verification protocol Validation Prepare validation protocol
Test the ranges provided by the manufacturer and technical variables in the laboratory Include variables influencing assay performance

Amount of input DNA

Number, type of samples in sequencing run

Sequencing machine and other instruments

Personnel

Verify the values provided by the manufacturer Assess parameters describing the test performance

Limit of blank, limit of detection

Repeatability, reproducibility

Proportion of true/false positives/negatives, etc. (See Supplementary Table 3)

Quality control (QC) and continuous monitoring

Diagnostic samples

Regularly analyzed positive and negative controls

Monitor of specimen parameters Sample purity, DNA quality, etc.
Check variant profile Proportion of TP53-mut/del(17p) and low-burden TP53 mutations, variant profile (Figs. 1, 4, 6)
Samples supplied by EQA provider External quality assessment (EQA)
Samples provided by independent laboratory Interlaboratory comparison

aWhen using commercial research-use-only tests, the steps of test development and optimization are the same as for IVD/IVDR assays, but full validation must be performed.